Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year

Cardiology

Volumn 120, Issue 1, 2011, Pages 43-49

  Iversen, Allan Zeeberg ^a   Galatius, Soeren ^a   Abildgaard, Ulrik ^a   Galloe, Anders ^c   Hansen, Peter Riis ^a   Pedersen, Sune ^a   Engstroem, Thomas ^a   Jensen, Jan Skov ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

Author keywords

Abciximab; Intracoronary administration; Intravenous administration; Primary percutaneous coronary intervention; ST segment elevation myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY STENT; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REINFARCTION; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK ASSESSMENT; RISK REDUCTION; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TARGET VESSEL REVASCULARIZATION; TREATMENT DURATION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 82055178498     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000333117     Document Type: Article

References (36)

1. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-961.
2. The CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-1435.
3. The EPIC Investigators: Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886.
4. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neuman FJ, Van de Werf F, Antman EM, Topol EJ: Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293: 1759-1765.
5. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E: Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European metaanalysis on individual patients' data with long-term follow-up. Eur Heart J 2007; 28: 443-449. (Pubitemid 47343560)
6. Ndrepepa G, Kastrati A, Mehilli J, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Dirschinger J, Berger PB, Schömig A: One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. Eur Heart J 2008; 29: 455-461. (Pubitemid 351264175)
7. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20. (Pubitemid 36050955)
8. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, Hochman JS, Krumholz HM, Lama GA, Mullany CJ, Pearle DL, Sloan MA, Smith SC Jr; 2004 Writing Committee Members, Anbe DT, Kuschner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007. Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117: 296-329.
9. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosenberg A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG): Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
10. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680-1688. (Pubitemid 28211416)
11. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-1764. (Pubitemid 24320922)
12. Collet JP, Montalescot G, Lesty C, Soria J, Mishal Z, Thomas D, Soria C: Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 2001; 21: 142-148. (Pubitemid 32061939)
13. Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL: An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 2002; 87: 1020-1025. (Pubitemid 34624885)
14. Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G: Intracoronary compared with intravenous bolus abciximab application in patients with STelevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 2008; 118: 49-57.
15. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP: Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004; 62: 186-192. (Pubitemid 38788695)
16. Romagnoli E, Burzotta F, Trani C, Mazzari MA, Biondi-Zoccai GG, De Vita M, Giannico F, Niccoli G, Prati F, Rebuzzi AG, Mongiardo R, Crea F: Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 2005; 105: 250-255. (Pubitemid 41605072)
17. Hansen PR, Iversen A, Abdulla J: Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J Invasive Cardiol 2010; 22: 278-282.
18. Wohrle J, Grebe OC, Nusser T, Al-khayer E, Schaible S, Kochs M, Hombach V, Höher M: Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 2003; 107: 1840-1843. (Pubitemid 36444121)
19. Kakkar AK, Moustapha A, Hanley HG, Weiss M, Caldito G, Misra P, Reddy PC, Tandon N: Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 2004; 61: 31-34. (Pubitemid 38036787)
20. Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, Pedersen S, Jensen KS, Jensen JS: Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial. J Interv Cardiol 2011; 24: 105-111.
21. Ellis SG, Vandormael MG, Cowley MJ: Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82: 1193-1202.
22. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium: Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351. (Pubitemid 46685903)
23. Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ: Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary versus Intravenous Abciximab Administration during Emergency Reperfusion of ST-Segment Elevation Myocardial Infarction (CICERO) trial. Circulation 2010; 122: 2709-2717.
24. Gu YL, Fokkema ML, Kampinga MA, de Smet BJ, Tan ES, van den Heuvel AF, Zijlstra F: Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration. Trials 2009; 10: 90.
25. Iversen A, Galatius S, Jensen JS: The optimal route of administration of the glycoprotein IIb/IIIa receptor antagonist abciximab during percutaneous coronary intervention; intravenous versus intracoronary. Curr Cardiol Rev 2008; 4: 293-299.
26. Goto S, Tamura N, Ishida H: Ability of antiglycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004; 44: 316-323. (Pubitemid 38950589)
27. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS: Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J Clin Invest 1996; 98: 863-874. (Pubitemid 26349192)
28. Romagnoli E, Burzotta F, Trani C, Biondi-Zoccai GG, Giannico F, Crea F: Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 2007; 23: 57-63.
29. Topol EJ, Byzova TV, Plow EF: Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-231. (Pubitemid 29088046)
30. Capodanno D, Prati F, Pawlowsky T, Ramazzotti V, Albertucci J, La Manna A, Robert G, Tamburino C: ClearWayRX system to reduce intracoronary thrombus in patients with acute coronary syndromes according to optical coherence tomography after abciximab intracoronary local infusion trial (COCTAIL): study rationale and design. J Cardiovasc Med (Hagerstown) 2010; 11: 130-136.
31. Thiele H, Wohrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuelen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burkhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G; Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators: Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. Am Heart J 2010; 159: 547-554.
32. Bertrand OF, Rodes-Cabau J, Larose E, Rinfret S, Gaudreault V, Proulx G, Barbeau G, Déry JP, Gleeton O, Manh-Nguyen C, Noël B, Roy L, Costerousse O, Larochelliére R; EArly Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASY-MI) Study Investigators: Intracoronary compared to intravenous abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study. Am J Cardiol 2010; 105: 1520-1527.
33. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockage vs heparin and planned glycoprotein IIb/IIIa blockage during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292: 696-703. (Pubitemid 39062523)
34. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ; ACUITY Investigators: Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007; 298: 2497-2506. (Pubitemid 350223536)
35. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW; HORIZONS-AMI Trial Investigators: Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009; 374: 1149-1159.
36. Gidlöf O, Andersson P, van der Pals J, Götberg M, Erlinge D: Cardiospecific micro-RNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011; 118: 217-226.